Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Melanie N. Shackett"'
Autor:
Robert H. Scannevin, Kenneth J. Rhodes, Mi Young Jung, Matvey E. Lukashev, Sowmya Chollate, Melanie N. Shackett, Masayuki Yamamoto, Weike Zeng, Sarah Ryan, Hiral Patel, Pradeep Bista
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 341:274-284
Oxidative stress is central to the pathology of several neurodegenerative diseases, including multiple sclerosis, and therapeutics designed to enhance antioxidant potential could have clinical value. The objective of this study was to characterize th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::726689985fd6f8b86aa0a8ad08c76553
https://doi.org/10.1124/jpet.111.190132
https://doi.org/10.1124/jpet.111.190132
Autor:
Robert H. Scannevin, Tina Talreja, Lin Xu, Gnanasambandam Kumaravel, David Kocisko, Arthur G. Taveras, Anthone W. Dunah, Hairuo Peng, Kenneth J. Rhodes, Ellen Rohde, H. Moore Arnold, Sowmya Chollate, Pamela A. Snodgrass-Belt, Mi-yong Jung, Andrew Zhang, Zhili Xin, Melanie N. Shackett
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 21:7277-7280
Starting from literature examples of nonsteroidal anti-inflammatory drugs (NSAIDs)-type carboxylic acid γ-secretase modulators (GSMs) and using a scaffold design approach, we identified 4-aminomethylphenylacetic acid 4 with a desirable γ-secretase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fff16ea306e260e39cfe769d34265e32
https://doi.org/10.1016/j.bmcl.2011.10.047
https://doi.org/10.1016/j.bmcl.2011.10.047
Autor:
Tina Talreja, Arthur G. Taveras, Michael Humora, Lawrence Gan, J. Hernan Cuervo, Kenneth J. Rhodes, Hairuo Peng, Lin Xu, Anthone W. Dunah, Gnanasambandam Kumaravel, Pamela A. Snodgrass-Belt, Mi-young Jung, Zhili Xin, Sowmya Chollate, Melanie N. Shackett, Ellen Rohde, H. Moore Arnold, Robert H. Scannevin
Publikováno v:
ACS Medicinal Chemistry Letters. 2:786-791
We have investigated a novel series of acid-derived γ-secretase modulators as a potential treatment of Alzheimer's disease. Optimization based on cellular potency and brain pharmacodynamics after oral dosing led to the discovery of 10a (BIIB042). Co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5f8cd4a82fc2be0e7dceb3dc620003c
https://doi.org/10.1021/ml200175q
https://doi.org/10.1021/ml200175q